References
- Lloyd-Still JD. Text book of cystic fibrosis. John Wright-PSG Inc., Boston 1983
- di Sant' Agncse P A, Davis PB. Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature. Am J Med 1979; 66: 121–132
- Penketh A RL, Wise A, Mearns M B, Hodson M E, Batten JC. Cystic fibrosis in adolescents and adults. Thorax 1987; 42: 526–532
- Kraemer R, Rudeberg A, Hodorn B, Rossi E. Relative underweight in cystic fibrosis and its prognostic value. Acta Paediatr Scand 1978; 67: 33–37
- Neijens HJ, Duiverman EJ, Kerrehijn KF. Influence of respiratory exacerbations on lung function variables and nutritional status in CF patients. Acta Paediatr Scand 1985; 317: 38–41, suppl
- Marcotte J E, Canny G J, Crisdale R, et al. Effects of nutritional status on exercise performance in advanced cystic fibrosis. Chest 1986; 90: 375–379
- Stead RJ, Skypala I, Hodson ME, Batten JC. Enteric coated microspheres of pancreatin on the treatment of cystic fibrosis: comparison with a standard enteric coated preparation. Thorax 1987; 42: 533–537
- Di Magno E P, Malagelade J R, Go V L, Moutel CG. Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules. N Engl J Med 1977; 296: 1318–1322
- Graham DY. Enzyme replacement therapy of exocrine pancreatic insufficiency in man. Relations between in vitro enzyme activities and in vivo potency in commercial pancreatic extracts. N Engl J Med 1977; 296: 1314–1317
- Regan P T, Malagelade JR, DiMagno EP, et al. Reduced intraluminal bile acid concentrations and fat maldigestion in pancreatic insufficiency; correction by treatment. Gastroenterology 1979; 77: 285–289
- Zentler-Munro P L, Five D R, Batten J C, Northficld TC. Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis. Gut 1985; 26: 892–901
- Gow R, Francis P, Bradbear R, Shepherd R. Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fribrosis; effectiveness of an enteric-coated preparation with and without antacids and cimetidine. Lancet 1981; 2: 1071–1074
- Brogden R N, Carmine A A, Heel R C, Speight T M, Avery GS. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1982; 24: 267–303
- Cleghorn GJ, Shepherd RW, Holt TL. The use of a synthetic prostaglandin E, analogue (misoprostol) as an adjunct to pancreatic enzyme replacement in cystic fibrosis. Scand J Gastroenterol 1988; 23: 142–147, suppl 143
- Smeaton L A, Hirst B M, Allen A, Garner A. Gastric and duodenal HCO3− transport in vivo: influence of prostaglandins. Am J Physiol 1983; 245: G751–759
- Goa K L, Monk JP. Enprostil. Drugs 1987; 34: 539–559
- Van der Kamer J. Standard methods of clinical chemistry, D Seligson. Academic Press, New York 1958; Vol. 2.: 34
- Vantrappen G, Janssens J, Popick T., et al. Effect of 15(R)-15-methylprostaglandin E2 (arboprostil) on the healing of duodenal ulcer. Gastroenterology 1982; 83: 357–363
- Lamers C BHW. Cimetidine or ranitidine. Ned Tijdschr Geneeskd 1986; 130: 1479–1481
- Anonymous. Cimetidine and ranitidine. Lancet 1982; 1: 601–602
- Anonymous. H-,-receptor antagonists–cimetidine and ranitidine. Br Med J 1983; 286: 695–697
- Crampton JR, Gibbons LC, Rees WDW. Effect of luminal pH on the output of bicarbonate and PGE, by the normal stomach. Gut 1987; 28: 1291–1295
- Baxter P S, Read N W, Hardcastle P T, Wilson A J, Hardcastle J, Taylor CJ. Abnormal jejunal potential difference in cystic fibrosis. Lancet 1989; 1: 464–466
- Welsh M J, Fick RB. Cystic fibrosis. J Clin Invest 1987; 80: 1523–1526